GlassScriptPhysician profile
Alex Edward Heaton
NPI 1649563842
$8,590.15
in general payments reported to CMS, 2019-2025
26 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $145 · 2021: $588 · 2022: $1,147 · 2023: $4,181 · 2024: $1,094 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,000 · Food and Beverage: $2,521 · Travel and Lodging: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,000.00 |
| Food and Beverage | $2,521.03 |
| Travel and Lodging | $745.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trisalus Life Sciences, INC. | $3,532.79 | 2023 | Trinav Infusion System |
| Siemens Medical Solutions USA, INC. | $736.81 | 2022-2025 | Cios Spin |
| Nevro Corp. | $678.78 | 2024 | Senza |
| Boston Scientific Corporation | $488.77 | 2021-2025 | Eluvia, Obsidio, Therasphere360_pi |
| Shockwave Medical, INC | $431.91 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Penumbra, INC. | $430.28 | 2020-2025 | Indigo System |
| Medtronic, INC. | $323.32 | 2021-2023 | Hawkone |
| Bard Peripheral Vascular, INC. | $255.67 | 2019-2025 | Venovo, Wavelinq |
| Stryker Corporation | $218.00 | 2019-2021 | |
| Clinical Technology, INC | $192.48 | 2023 | |
| Inari Medical, INC. | $189.43 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Davol INC. | $159.60 | 2022 | |
| Veryan Medical Incorporated | $145.23 | 2024 | Biomimics 3d Vascular Stent System |
| Angiodynamics, INC. | $141.72 | 2021 | |
| Sirtex Medical INC | $125.88 | 2025 | Sir-Spheres Microspheres |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Access Systems, INC. | $107.91 | 2019 | |
| Terumo Medical Corporation | $79.90 | 2021-2025 | Glidewire, Angio-Seal, Azur Cx Detachable |
| Philips North America LLC | $70.19 | 2019 | |
| Argon Medical Devices, INC. | $67.28 | 2019 | |
| Cook Medical LLC | $58.03 | 2021-2024 | Tornado |
| Janssen Biotech, INC. | $47.75 | 2024-2025 | Erleada |
| Profound Medical Corp. | $28.56 | 2025 | Tulsa-Pro |
| Surmodics, INC. | $23.97 | 2023 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Microcatheter, 014, 65cm, Straight, Sublime Microcatheter, 014, 65cm, Angle |
| Janssen Pharmaceuticals, INC | $21.43 | 2021 | |
| Becton, Dickinson and Company | $20.19 | 2022 | |
| Tolmar, INC. | $14.27 | 2025 | Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Heaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.